pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
230
stories
May 1, 26
Amgen launches late-stage obesity trial in patients who switch from rival drugs
endpoints
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
Apr 30, 26
STAT+: Hair-raising trial results, and Servier’s M&A wishlist
stat
Apr 30, 26
Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
endpoints
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
Apr 30, 26
STAT+: Five-way obesity drug is super effective — in mice
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
Apr 30, 26
Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s
endpoints
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
Apr 29, 26
STAT+: A patent win for Pfizer and BridgeBio
stat
Apr 28, 26
STAT+: FDA launches effort to speed up clinical trials, using AI
stat
Apr 28, 26
Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests
stat
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
stat
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 28, 26
STAT+: Eli Lilly enlists AI startup for next-generation gene editors
stat
Apr 27, 26
Lilly to buy startup Ajax in bid for a better JAK drug
biopharma dive
Apr 27, 26
STAT+: Astellas retries XLMTM gene therapy after deaths
stat
Apr 27, 26
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
endpoints
Dec 23, 25
Fierce Biotech Layoff Tracker 2026: Amgen sheds staff; Clinuvel cuts fifth of workforce
fiercebiotech
← prev
page 8 of 8
next →
